Camizestrant

A selective estrogen receptor degrader

Camizestrant
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Camizestrant is a selective estrogen receptor degrader (SERD) that is being investigated for the treatment of hormone receptor-positive breast cancer. It is designed to bind to the estrogen receptor and promote its degradation, thereby inhibiting the growth of cancer cells that rely on estrogen signaling.

Mechanism of Action

Camizestrant functions by targeting the estrogen receptor (ER) for degradation. Unlike traditional selective estrogen receptor modulators (SERMs), which block the receptor, SERDs like camizestrant lead to the receptor's destruction. This process reduces the number of receptors available for estrogen binding, effectively diminishing the estrogen-driven proliferation of cancer cells. This mechanism is particularly beneficial in breast cancer cases that have developed resistance to other forms of endocrine therapy.

Clinical Development

Camizestrant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with advanced or metastatic hormone receptor-positive breast cancer. These trials aim to determine the optimal dosing regimen and to compare the effectiveness of camizestrant with existing therapies such as fulvestrant and aromatase inhibitors.

Potential Benefits

The development of camizestrant represents a significant advancement in the treatment of hormone receptor-positive breast cancer. By offering a novel mechanism of action, camizestrant has the potential to overcome resistance to current endocrine therapies. This could provide a new line of treatment for patients who have limited options due to the progression of their disease.

Side Effects

As with any therapeutic agent, camizestrant may have side effects. Commonly observed adverse effects in clinical trials include nausea, fatigue, and hot flashes. Ongoing studies continue to monitor the safety profile of camizestrant to ensure its benefits outweigh any potential risks.

Related pages

• Breast cancer
• Estrogen receptor
• Selective estrogen receptor degrader
• Fulvestrant
• Aromatase inhibitor